https://www.pharmaceutical-technology.com/news/gsk-rise-profit-q2-2023/ 2023-07-27T08:37:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-calibr-advancement-clinical-assets/ 2023-07-27T08:42:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/global-private-equity-activity-pharmaceutical-industry/ 2024-12-02T16:26:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/top-10-ma-legal-advisers-h1-2023-asia-pacific-2/ 2023-07-26T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/top-10-ma-financial-advisers-h1-2023-asia-pacific-2/ 2023-07-26T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/comment/what-does-2023s-property-investor-look-like/ 2023-07-26T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/oncology-biosimilar-case-studies-bevacizumab/ 2023-07-26T16:33:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/trial-investigating-peanut-allergy-immunotherapy-hits-final-milestone/ 2023-07-26T15:20:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-first-ever-therapy-demodex-blepharitis/ 2023-07-26T15:11:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/microgravity-the-future-of-rd/ 2023-07-26T13:55:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-tender-offer-dice/ 2023-07-26T10:43:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bioengineering-company-ossium-health-series-c/ 2023-07-26T10:42:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/boehringer-lilly-jardiance-adults-ckd/ 2023-07-26T08:08:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mirums-maralixibat-health-canada/ 2023-07-26T08:11:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sentiment-pharmaceutical-industry-decreased/ 2024-07-18T14:39:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/jobs/bigdata-hiring-pharmaceutical-industry/ 2024-07-19T04:30:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/jobs/futureofwork-hiring-pharmaceutical-industry/ 2024-08-22T12:49:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/comment/unravelling-the-western-investors-love-affair-asia/ 2023-07-25T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fdi-into-the-asia-pacific-region-in-2022/ 2023-07-25T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roche-snubs-sqz-hpv-16-programme-leaving-the-beleaguered-company-in-the-lurch/ 2023-07-25T16:24:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astellas-peptidream-discovery-deal/ 2023-07-25T13:40:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/alvotech-and-teva-step-up-biosimilars-partnership/ 2023-07-25T13:35:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/top-10-ma-legal-advisers-h1-2023-middle-east-africa/ 2023-08-07T11:23:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/top-10-ma-financial-advisers-h1-2023-middle-east-africa/ 2023-08-07T11:15:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-chmp-viiv-cabotegravir/ 2023-07-25T10:22:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/golgi-breye-p2x7-receptor-antagonist-programme/ 2023-07-25T10:25:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-cognizant-expand-deal/ 2023-07-25T09:16:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/immunogen-immunobiochem-partner-adcs-development/ 2023-07-25T09:14:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/middleeastandafrica-privateequitydeal-activity-pharmaceutical-industry/ 2024-09-10T02:25:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/top-10-ma-legal-advisers-h1-2023-middle-east-africa-2/ 2023-07-24T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/top-10-ma-financial-advisers-h1-2023-middle-east-africa-2/ 2023-07-24T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-innovation-just-explodes-the-role-of-ai-in-accelerating-biopharma-rd/ 2023-08-08T08:12:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-supports-sandozs-tysabri-biosimilar-amid-various-endorsements/ 2023-07-24T16:03:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bavarian-nordic-rsv-vaccine-phase-iii-failure/ 2023-07-24T13:57:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/hydrogen-as-a-gas-chromatography-carrier-gas/ 2023-07-24T14:20:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/redhill-funding-opaganib-development/ 2023-07-24T10:49:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/verrica-fda-approval-ycanth-molluscum/ 2023-07-24T10:55:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roche-alnylam-rnai-development/ 2023-07-24T07:47:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/epcoritamab-positive-opinion-chmp-lymphoma/ 2023-07-24T08:57:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/supercritical-fluids-advance-sterilisation-tech-in-pharma/ 2023-07-17T00:18:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/how-to-enter/ 2023-07-24T06:30:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/categories/ 2023-07-24T06:29:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/winners/ 2023-07-24T06:29:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/privateequity-activity-orphan-designated-drugs-pharmaceutical-industry/ 2024-11-08T03:43:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sn-bioscience-nano-cancer-therapy-wins-orphan-drug-designation/ 2023-07-21T15:40:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/immunotherapy-insights-oncolytic-viruses-struggle-to-find-a-spot-in-a-crowded-field/ 2023-07-26T14:07:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/top-10-ma-legal-advisers-h1-2023-south-central-america/ 2023-08-07T13:52:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/top-10-ma-financial-advisers-h1-2023-south-cental-america/ 2023-08-07T13:39:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/idorsia-asia-pacific-operations/ 2023-07-21T12:48:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cidara-cd388-influenza-programme-janssen/ 2023-07-21T12:36:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/controlling-pharma-machine-ema-ai/ 2023-07-21T11:46:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/adc-terminates-phase-ii-trial-lymphoma-therapy/ 2023-07-21T10:50:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/johnson-q2-2023-sales/ 2023-07-21T10:26:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/epibiologics-names-ceo-president/ 2023-07-21T10:27:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-daiichi-sankyo-aml/ 2023-07-21T09:02:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fruquintinib-sintilimab-combo-breakthrough-china/ 2023-07-21T07:39:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/top-10-ma-legal-advisers-h1-2023-south-central-america-2/ 2023-07-20T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/top-10-ma-financial-advisers-h1-2023-south-cental-america-2/ 2023-07-20T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vienna-named-top-city-in-the-world-for-eco-friendly-businesses/ 2023-07-20T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uae-pledges-51bn-of-bilateral-agreements-with-turkey/ 2023-07-20T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-grants-fast-track-status-for-astria-therapeutics-star-0215/ 2023-07-20T15:50:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/who-director-general-calls-out-critics-planned-pandemic-accords/ 2023-07-20T15:38:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/iovance-ln-145-relapsed-nsclc-patients/ 2023-07-20T14:34:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sandoz-invests-90m-biosimilar-centre-slovenia/ 2023-07-20T13:05:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nih-funds-2m-ai-project-for-predicting-cancerous-lesions/ 2023-07-20T12:07:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/preventative-measures-rsv-market/ 2023-07-20T12:01:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roche-vabysmo-reports-positive-outcomes-multiple-eye-diseases/ 2023-07-20T10:28:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/genedx-prognos-rare-diseases/ 2023-07-20T10:19:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-fast-track-status-ambrx/ 2023-07-20T10:20:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-refuses-authorisation-ipsen/ 2023-07-20T08:23:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/scg-cell-therapy-facility-singapore/ 2023-07-20T07:18:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jobs-signal-generative-ai-postings-skyrocket/ 2023-07-20T04:10:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/asian-countries-prioritise-rare-disease-market-access-amid-stark-disparities/ 2023-07-20T08:09:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/how-can-the-east-african-community-fulfil-its-fdi-potential/ 2023-07-19T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pieris-pharma-lays-off-70-of-workforce-amid-company-restructuring/ 2023-07-19T17:09:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amarin-restructure-downturn-vascepa-generics/ 2023-07-19T16:37:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/us-dod-enlists-vitrivax-to-develop-one-shot-vaccine-for-melioidosis/ 2023-07-19T16:23:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/santhera-and-catalyst-to-market-dmd-drug-vamorolone-in-north-america/ 2023-07-19T15:46:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-q2-2023-sales/ 2023-07-19T10:42:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/advent-nih-grant-therapy/ 2023-07-19T10:02:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/telix-adds-another-trial-targeted-radiation-therapy-development-programme/ 2023-07-19T15:26:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/flagship-pioneering-collaborates-pfizer/ 2023-07-19T08:43:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/twist-cancer-research-horizons-antibody-platform/ 2023-07-19T07:32:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/us-companies-tax-russia-billions-sanctions-profits/ 2023-07-18T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-snaps-up-rare-disease-biotech-dtx-pharma-in-1bn-deal/ 2023-07-18T17:51:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/highlights-eha-congress-2023-allogeneic-cell-therapy-updates/ 2023-07-18T16:15:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-astrazeneca-rsv-monoclonal-antibody-treatment-infants/ 2023-07-18T15:42:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/neoleukin-merge-neurogene-200m-cash-reserves/ 2023-07-18T14:45:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eu-prepares-winter-plans-antibiotic-shortage/ 2023-07-18T14:25:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-next-generation-of-pharmaceutical-supply-chain-innovation-has-arrived-are-you-prepared/ 2023-08-30T16:18:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/4dmt-clinical-programme-updates-wet-amd-gene-therapy/ 2023-07-31T07:10:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-reclassification-cough-syrup/ 2023-07-18T10:38:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sangamo-agreement-aav-capsids/ 2023-07-18T10:42:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-impact-of-ai-and-chatgpt-on-health-data/ 2023-12-14T11:52:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/scribe-sanofi-expand-deal/ 2023-07-18T08:28:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mirum-travere-bile-acid-products/ 2023-07-18T08:23:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/patents-signal-china-leads-with-patent-filings-in-pharma-in-q2/ 2023-07-18T02:45:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/comment/why-geopolitical-risk-should-inform-esg-strategies/ 2023-07-17T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/what-is-the-black-sea-grain-initiative-ukraine-grain-deal/ 2023-07-17T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/viral-genome-characterisation-facilitated-by-the-agilent-5200-fragment-analyzer-system/ 2024-02-28T10:37:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-veklury-covid-19-severe-kidney-disease/ 2023-07-17T14:55:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eleven-novo-nordisk-partner-develop-nucleic-acid-therapeutics/ 2023-07-17T14:37:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/snipr-celebrates-us-courts-favourable-ruling-on-crispr-patent/ 2023-07-17T14:04:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cai-facility-cancer/ 2023-07-17T10:14:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/antengene-approval-hong-kong/ 2023-08-29T04:10:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/korro-bio-merger-frequency/ 2023-07-26T12:28:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-to-acquire-versanis/ 2023-07-17T08:20:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/fighting-amr-with-a-value-and-subscription-model/ 2023-07-15T15:06:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jobs-signal-general-and-operational-jobs-in-demand-in-pharma/ 2023-07-19T13:40:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bicycle-therapeutics-plans-200m-public-offering/ 2023-07-14T16:27:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/causaly-secures-60-million-in-series-b-funding/ 2023-07-14T16:19:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/coherus-plans-humira-biosimilar-sale-85-discount/ 2023-07-14T15:46:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jj-allows-generic-production-for-tb-drug-following-public-dissent/ 2023-07-14T15:45:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/curevac-turns-up-the-heat-in-ongoing-patent-litigation-with-pfizer/ 2023-07-14T14:07:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-transformative-impact-of-digitalization-in-biopharma/ 2024-07-01T16:28:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/theseus-terminates-its-gi-cancer-drug-development-programme/ 2023-07-14T13:48:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vistagen-canada-av-101-patent/ 2023-07-14T10:04:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-hiv-treatment-children/ 2023-07-14T09:48:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/health-canada-astrazeneca-prostate-cancer/ 2023-07-14T08:12:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/emmaus-authorisation-sickle-cell/ 2023-07-14T08:47:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/interviews/angolas-economic-rebound-and-the-impact-of-the-zee-free-trade-zone/ 2023-07-13T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-greenlights-first-over-the-counter-birth-control-pill/ 2023-08-19T17:00:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/actimed-plans-trials-to-treat-muscle-wasting-syndrome-in-cancer-patients/ 2023-07-13T16:18:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nvidia-invests-50m-in-ai-enabled-drug-discovery/ 2023-07-13T21:08:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aridiss-ar-301-monoclonal-antibody-to-receive-fda-qidp-designation/ 2023-07-13T15:37:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sectors/healthcare/atrial-fibrillation-market-decline/ 2023-07-13T15:27:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/pricing-and-market-access/hta-5eu-oncology/ 2023-07-14T15:31:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roche-eyes-alternate-mode-administration-ocrevus-in-ms/ 2023-07-13T14:10:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tenpoint-cell-therapies-vision-loss/ 2023-07-13T10:13:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-beigene-snda-follicular-lymphoma/ 2023-07-13T09:57:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/icr-cancer-drug-partnership/ 2023-07-13T08:04:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-astrazeneca-daiichi-sankyo/ 2023-07-13T07:36:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/deal-focus-chinas-byd-investment-in-brazil-shows-strength-of-brics/ 2023-07-12T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/infosys-embarks-on-canada-public-services-investment-spree/ 2023-07-12T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nhs-doubles-down-on-netflix-style-antibiotic-subscription-model/ 2023-07-12T17:58:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-concern-suicide-risk-glp-1ras-drugs/ 2023-07-12T15:34:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/skyelarke-makes-public-significant-changes-to-skyepay/ 2023-07-12T16:20:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/imperial-spinout-wins-1-6m-innovate-uk-grant-for-nk-cell-therapies/ 2023-07-12T15:06:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/canada-fshd-rare-muscle-dystrophy-therapy/ 2023-07-12T15:04:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cingulate-fda-approval-adhd-pill/ 2023-07-12T12:27:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/crossbow-series-a-funds/ 2023-07-12T09:37:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/synlogic-phenylketonuria-therapy-fda/ 2023-07-12T09:29:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/takeda-bla-dengue-vaccine/ 2023-07-12T07:25:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/septerna-series-b-funding/ 2023-07-12T07:18:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/virpax-plans-three-trials-based-on-platform-drug-delivery-systems-in-2024/ 2023-07-12T17:08:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/covid-19-anti-inflammatory-drugs-do-not-lead-to-a-swifter-hospital-exit/ 2023-07-12T12:35:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/israeli-company-bags-4-2m-contact-develop-cell-therapy-for-radiation-poisoning/ 2023-07-11T15:51:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roches-columvi-receives-marketing-approval-in-europe/ 2023-07-11T15:41:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-to-ensure-transparency-in-your-clinical-trial/ 2024-02-06T12:10:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/iovance-looks-to-advance-its-non-small-cell-lung-cancer-therapy/ 2023-07-11T10:16:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fulcrum-camp4-signs-deal/ 2023-07-11T09:55:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astellas-licenses-4dmt-vector/ 2023-07-11T10:26:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/beigene-acquire-adc-therapy/ 2023-07-11T08:26:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/elsie-gsk-oligonucleotide-platform/ 2023-07-11T08:24:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-approves-gsks-rsv-vaccine-for-older-adults-in-the-uk/ 2023-07-10T17:15:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/hhs-cracks-down-on-hidden-insurance-fees/ 2023-07-10T16:50:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-plans-appeal-to-ward-off-entresto-generics/ 2023-08-14T19:17:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nanobiotix-partners-with-janssen-to-commercialise-radioenhancer-oncology-drug/ 2023-07-10T14:58:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-label-expansion-for-novartis-leqvio/ 2023-07-10T21:46:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/investor-sentiment-us-companies/ 2023-07-10T12:45:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sectors/healthcare/triple-negative-breast-cancer-treatment/ 2023-07-10T10:59:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/igc-pharma-alzheimers-research/ 2023-07-10T10:40:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/zyversa-asset-patent-europe/ 2023-07-10T09:49:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ns-pharma-rare-paediatric-disease/ 2023-07-10T08:49:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ichnos-fda-orphan-drug-status/ 2023-07-10T08:47:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/magazine-ai-for-patients-hype-or-hope/ 2023-08-02T16:56:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/can-iraq-now-dream-of-attracting-foreign-investment-fdi/ 2023-07-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-101-abbvie-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T02:19:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oncolytic-virus-for-human-papillomavirus-associated-cancer-human-papillomavirus-infections-and-coronavirus-disease-2019-covid-19-blue-sky-immunotherapies-cervical-intraepithelial-neoplasia-cin-likelih/ 2023-07-08T01:43:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kns-366-kynos-therapeutics-pancreatitis-likelihood-of-approval/ 2023-07-08T01:43:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fibromun-philogen-malignant-glioma-likelihood-of-approval/ 2025-01-19T18:19:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-101-abbvie-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T02:18:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/purinostat-mesylate-chengdu-zenitar-biomedical-technology-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-19T18:20:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/octreotide-la-camurus-neuroendocrine-tumors-likelihood-of-approval/ 2025-01-19T18:19:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tpiv-110-marker-therapeutics-ductal-carcinoma-in-situ-likelihood-of-approval/ 2024-05-20T02:36:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-101-abbvie-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T02:19:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-111-biontech-metastatic-melanoma-likelihood-of-approval/ 2024-05-20T02:36:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oncolytic-virus-for-human-papillomavirus-associated-cancer-human-papillomavirus-infections-and-coronavirus-disease-2019-covid-19-blue-sky-immunotherapies-human-papillomavirus-infections-likelihood-of/ 2023-12-21T15:18:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-101-abbvie-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T02:18:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tmegfr-il13ralpha2-01-car-t-kite-pharma-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-05-20T02:37:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-101-abbvie-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T02:19:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nnc0519-0130-novo-nordisk-type-2-diabetes-likelihood-of-approval/ 2024-05-20T02:38:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agt103-t-addimmune-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-04-19T16:47:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inc-005-hk-inno-n-helicobacter-pylori-infections-likelihood-of-approval/ 2023-07-08T01:40:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-110-crispr-therapeutics-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-07-05T05:59:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fibromun-philogen-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-19T18:19:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-101-abbvie-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2024-09-09T02:19:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regn-9933-regeneron-pharmaceuticals-venous-thromboembolism-likelihood-of-approval/ 2023-07-08T01:39:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-16673-beigene-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:20:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-101-abbvie-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T02:19:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-101-abbvie-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-09-09T02:19:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ac-0676-accutar-biotechnology-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:20:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lovotibeglogene-autotemcel-bluebird-bio-sickle-cell-disease-likelihood-of-approval/ 2024-02-08T03:40:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camlipixant-gsk-chronic-cough-likelihood-of-approval/ 2025-01-19T18:19:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-101-abbvie-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2024-09-09T02:19:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irl-201104-revolo-biotherapeutics-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2025-01-19T18:19:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-106-mustang-bio-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:19:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-101-abbvie-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T02:18:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hydrocodone-ir-elysium-therapeutics-opium-opioid-addiction-likelihood-of-approval/ 2023-07-08T01:37:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gmcn-508a-genmedicn-biopharma-alpha-thalassaemia-likelihood-of-approval/ 2023-07-08T01:37:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/purinostat-mesylate-chengdu-zenitar-biomedical-technology-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-19T18:20:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-101-abbvie-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T02:19:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crenigacestat-eli-lilly-and-co-natural-killer-cell-lymphomas-likelihood-of-approval/ 2024-09-09T02:17:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zorevunersen-sodium-stoke-therapeutics-net-present-value/ 2024-07-02T02:04:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utreloxastat-ptc-therapeutics-net-present-value/ 2024-06-13T18:53:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/povorcitinib-incyte-net-present-value/ 2024-07-02T02:10:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/antidepressant-prescriptions-continue-to-steadily-grow-in-england/ 2023-07-14T23:00:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eu-grants-full-marketing-authorisation-novavax-covid-19-vaccine/ 2023-07-07T15:38:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-caribou-biosciences/ 2023-07-26T12:29:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/optimising-production-time-and-quality-with-the-latest-innovations-in-cryo-milling/ 2023-07-07T10:49:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approval-eisai-alzheimers/ 2023-07-07T10:43:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/thermo-fisher-corevitas/ 2023-07-07T14:16:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/shorla-licence-chemotherapy-drug/ 2023-07-07T08:22:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astellas-priority-review-bla/ 2023-07-07T08:15:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-grants-orphan-drug-designation-to-impacts-focal-cancer-therapy/ 2023-07-06T17:20:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-endorsed-statement-targets-covid-19-vaccine-misinformation/ 2023-07-06T15:00:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/wcd-2023-atopic-dermatitis-color/ 2023-07-06T14:24:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sk-bioscience-vaccine-infrastructure/ 2023-07-06T14:04:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/marketing-pain-management-targeting-for-success/ 2023-07-17T14:17:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vbi-hepatitis-b-partnership/ 2023-07-06T10:49:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lifera-sanofi-arabio-saudi-arabia/ 2023-07-06T10:50:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/f-star-takeda-antibody-deal/ 2023-07-06T08:31:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/evotec-us-contract-antibody/ 2023-07-06T07:20:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uae-establishes-investment-ministry-fdi/ 2023-07-05T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/incyte-non-segmental-vitiligo-treatment-approved-in-uk/ 2023-07-05T15:54:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-corporate-plan-drug-regulatory-uk/ 2023-07-05T15:12:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-vertex-orkambi-cystic-fibrosis/ 2023-07-05T14:28:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fsd-pharma-new-ceo/ 2023-07-05T10:38:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ose-immunotherapeutics-tedopi-patent/ 2023-07-05T10:02:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nhs-drug-premature-babies/ 2023-07-05T08:13:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/rarestone-narcolepsy-therapy-china/ 2023-07-05T08:03:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/comment/digital-health-tech-a-solution-to-substance-use-disorders/ 2023-07-05T04:53:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/foreign-companies-made-214bn-in-russia-2022/ 2023-07-04T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/global-fdi-to-developed-economies-declined-2022-world-investment-report/ 2023-07-04T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/least-developed-countries-fdi-2022-unctad/ 2023-07-04T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/unctad-world-investment-report-global-foreign-direct-investment-declined-by-11-in-2022/ 2023-07-04T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/labcorp-forms-spin-off-of-fortrea/ 2023-07-04T15:57:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-skyline-therapeutics-ind-for-macular-degeneration-trial/ 2023-07-04T15:54:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/three-ways-to-improve-participant-engagement-in-your-digital-clinical-trials/ 2023-09-19T14:51:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amneal-receives-xyrem-generic-approval-after-patent-disputes/ 2023-07-04T14:01:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tonix-acquires-products-migraine/ 2023-07-04T13:34:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/venous-thromboembolism-2022-2032/ 2023-07-04T13:10:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abeona-funds-cell-therapy/ 2023-07-04T10:42:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/northx-acquires-valneva-unit/ 2023-07-04T10:22:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/cancer-immunotherapy-month-2022-record-number-approvals/ 2023-07-04T09:45:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-amneal-parkinsons-treatment/ 2023-07-04T08:51:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/moderna-ema-covid-vaccine/ 2023-07-04T08:52:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/rationing-strategies-proliferate-with-cancer-drugs-in-short-supply/ 2023-07-05T17:08:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/comment/how-to-trade-surprise-economic-data/ 2023-07-03T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/zealand-pharma-submits-nda-for-hyperinsulinism-drug-dasiglucagon/ 2023-07-03T15:52:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/pricing-and-market-access/vpa-fallout-celltrion-biosimilar-uk/ 2023-07-03T15:11:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/camena-bags-10m-in-funding-from-mercia/ 2023-07-03T14:31:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/baudax-bio-acquires-teraimmune/ 2023-07-03T17:00:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/generative-ai-beyond-the-hype/ 2023-07-03T13:39:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cyltezo-pen-first-interchangeable-biosimilar-to-humira-rolls-out-across-us/ 2023-07-03T13:04:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/eli-lilly-retatrutide-weight-loss-obesity/ 2023-08-07T13:06:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-innovent-myeloma-therapy/ 2023-07-03T17:00:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/madrigal-nash-treatment/ 2023-07-03T08:58:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chime-leads-beigene-antibody-deal/ 2023-07-03T08:19:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/us-health-care-costs/ 2023-07-03T08:21:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/corporate-profits-responsible-for-almost-half-of-europes-inflation-imf-report/ 2023-07-02T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/how-is-the-us-economy-performing-joe-biden-fdi/ 2023-07-02T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snk-396-synerk-lipid-disorders-likelihood-of-approval/ 2023-07-01T03:36:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/resiquimod-surge-therapeutics-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2023-07-01T03:35:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-4888-comanche-biopharma-pre-eclampsia-likelihood-of-approval/ 2023-07-01T03:34:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adipose-tissue-derived-mesenchymal-stromal-stem-cells-cell2cure-diabetic-foot-ulcers-likelihood-of-approval/ 2025-01-19T18:18:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brii-297-brii-biosciences-post-partum-depression-maternal-depression-postnatal-depression-likelihood-of-approval/ 2023-07-01T03:34:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yr-001-yirui-pharmaceutical-technology-psoriasis-likelihood-of-approval/ 2023-07-01T03:34:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yr-001-yirui-pharmaceutical-technology-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2023-07-01T03:34:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ckd-331-chong-kun-dang-pharmaceutical-hypertension-likelihood-of-approval/ 2024-01-24T19:05:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ckd-331-chong-kun-dang-pharmaceutical-hyperlipidemia-likelihood-of-approval/ 2024-09-09T04:25:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eb-203-eye-bio-korea-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2025-01-19T18:18:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/coya-301-coya-therapeutics-alzheimer-s-disease-likelihood-of-approval/ 2023-07-01T03:33:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tavo-103-tavotek-biotherapeutics-chronic-inflammation-likelihood-of-approval/ 2023-07-01T03:31:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vtx-3232-ventyx-biosciences-neuroinflammation-likelihood-of-approval/ 2025-01-19T18:18:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vtx-3232-ventyx-biosciences-parkinson-s-disease-likelihood-of-approval/ 2025-01-19T18:17:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hcp-1803-hanmi-pharmaceuticals-idiopathic-essential-hypertension-likelihood-of-approval/ 2023-07-01T03:30:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pra-052-merck-ulcerative-colitis-likelihood-of-approval/ 2024-02-21T23:59:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stp-707-sirnaomics-uveal-melanoma-likelihood-of-approval/ 2025-01-19T16:36:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wck-6777-wockhardt-complicated-intra-abdominal-infections-likelihood-of-approval/ 2023-07-01T03:29:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wck-6777-wockhardt-pyelonephritis-likelihood-of-approval/ 2023-07-01T03:29:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chm-1101-chimeric-therapeutics-astrocytoma-likelihood-of-approval/ 2024-06-14T02:07:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chm-1101-chimeric-therapeutics-malignant-glioma-likelihood-of-approval/ 2024-06-14T02:07:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgba-445-beigene-nasopharyngeal-cancer-likelihood-of-approval/ 2025-01-19T18:16:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-363-gilead-sciences-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-19T18:17:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-363-gilead-sciences-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-19T18:17:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-363-gilead-sciences-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:17:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-363-gilead-sciences-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:17:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-363-gilead-sciences-burkitt-lymphoma-likelihood-of-approval/ 2025-01-19T18:17:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-363-gilead-sciences-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:17:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-363-gilead-sciences-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T18:17:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-363-gilead-sciences-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:17:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vp-001-pyc-therapeutics-retinitis-pigmentosa-retinitis-likelihood-of-approval/ 2023-07-01T03:27:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aut-00201-autifony-therapeutics-myoclonic-seizure-likelihood-of-approval/ 2023-07-01T03:27:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aut-00201-autifony-therapeutics-ataxia-likelihood-of-approval/ 2023-07-01T03:27:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thn-391-therini-bio-alzheimer-s-disease-likelihood-of-approval/ 2025-01-19T18:16:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tara-002-protara-therapeutics-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2023-07-01T03:26:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mib-626-metro-international-biotech-acute-renal-failure-arf-acute-kidney-injury-likelihood-of-approval/ 2025-01-19T18:16:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cnty-101-century-therapeutics-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:16:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cnty-101-century-therapeutics-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:16:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-309309-shionogi-obesity-likelihood-of-approval/ 2023-07-31T01:16:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/k-757-kallyope-obesity-likelihood-of-approval/ 2025-01-19T18:15:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dazdotuftide-tarsier-pharma-glaucoma-likelihood-of-approval/ 2024-09-09T02:16:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dazdotuftide-tarsier-pharma-anterior-uveitis-likelihood-of-approval/ 2024-09-09T02:16:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/barzolvolimab-celldex-therapeutics-eosinophilic-esophagitis-likelihood-of-approval/ 2025-01-19T18:15:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vis-171-visterra-autoimmune-disorders-likelihood-of-approval/ 2024-09-09T02:15:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sp-101-spirovant-sciences-cystic-fibrosis-likelihood-of-approval/ 2025-01-19T18:15:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-summit-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:36:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebtate-molecular-targeting-technologies-neuroendocrine-gastroenteropancreatic-tumors-gep-net-likelihood-of-approval/ 2025-01-19T18:15:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agen-2373-agenus-castration-resistant-prostate-cancer-crpc-likelihood-of-approval/ 2025-01-19T18:15:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-110-crispr-therapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-07-05T05:55:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orelabrutinib-innocare-pharma-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:15:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orelabrutinib-innocare-pharma-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2025-01-19T18:15:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-222-gilead-sciences-mantle-cell-lymphoma-likelihood-of-approval/ 2024-06-14T02:06:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-222-gilead-sciences-burkitt-lymphoma-likelihood-of-approval/ 2024-06-14T02:06:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-222-gilead-sciences-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-06-14T02:06:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-222-gilead-sciences-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-06-14T02:06:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-19T16:36:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-222-gilead-sciences-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-06-14T02:06:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-222-gilead-sciences-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-06-14T02:06:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kite-222-gilead-sciences-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-06-14T02:06:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-melanoma-likelihood-of-approval/ 2025-01-19T18:14:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-101-abclon-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-06-14T02:05:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-101-abclon-mantle-cell-lymphoma-likelihood-of-approval/ 2024-06-14T02:05:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-101-abclon-follicular-lymphoma-likelihood-of-approval/ 2024-06-14T02:05:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-101-abclon-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-06-14T02:05:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-004-astrocyte-pharmaceuticals-acute-ischemic-stroke-likelihood-of-approval/ 2024-05-20T02:28:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cgx-1321-curegenix-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T18:14:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cgx-1321-curegenix-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-19T18:14:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cgx-1321-curegenix-esophageal-cancer-likelihood-of-approval/ 2025-01-19T18:14:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radspherin-oncoinvent-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-19T18:13:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radspherin-oncoinvent-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-19T18:13:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cnmau-8-clene-secondary-progressive-multiple-sclerosis-spms-likelihood-of-approval/ 2025-01-19T18:14:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cnmau-8-clene-primary-progressive-multiple-sclerosis-ppms-likelihood-of-approval/ 2025-01-19T18:14:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/laruparetigene-zovaparvovec-beacon-therapeutics-retinitis-pigmentosa-retinitis-likelihood-of-approval/ 2025-01-19T18:13:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T18:13:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lifirafenib-maleate-beigene-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:12:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-dae-hwa-pharmaceutical-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-19T18:12:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olx-101a-olix-pharmaceuticals-hypertrophic-scars-likelihood-of-approval/ 2023-07-01T03:12:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lifirafenib-maleate-beigene-ovarian-cancer-likelihood-of-approval/ 2025-01-19T18:12:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6101-innate-pharma-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-19T18:12:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6101-innate-pharma-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T18:12:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6101-innate-pharma-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T18:12:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6101-innate-pharma-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2025-01-19T18:12:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denifanstat-sagimet-biosciences-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-19T18:11:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-19T18:11:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-19T18:11:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:11:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-burkitt-lymphoma-likelihood-of-approval/ 2025-01-19T18:11:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:11:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T18:12:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asp-7317-astellas-pharma-dry-atrophic-macular-degeneration-likelihood-of-approval/ 2024-07-05T05:47:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asp-7317-astellas-pharma-juvenile-macular-degeneration-stargardt-disease-likelihood-of-approval/ 2024-07-05T05:47:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/resminostat-4sc-mycosis-fungoides-likelihood-of-approval/ 2025-01-19T18:10:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inclacumab-pfizer-sickle-cell-disease-with-vaso-occlusive-crisis-likelihood-of-approval/ 2023-07-01T03:07:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/n-115-emphycorp-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-19T18:10:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/resminostat-4sc-sezary-syndrome-likelihood-of-approval/ 2025-01-19T18:10:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-217-phanes-therapeutics-prostate-cancer-likelihood-of-approval/ 2025-01-19T18:09:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-217-phanes-therapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:09:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-217-phanes-therapeutics-neuroendocrine-gastroenteropancreatic-tumors-gep-net-likelihood-of-approval/ 2025-01-19T18:09:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:09:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:09:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-follicular-lymphoma-likelihood-of-approval/ 2025-01-19T18:09:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2025-01-19T18:09:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:09:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:09:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:09:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/memant-3310-antabio-acinetobacter-infections-likelihood-of-approval/ 2023-07-01T03:06:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/memant-3310-antabio-enterobacteriaceae-infections-likelihood-of-approval/ 2023-07-01T03:06:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trametinib-dimethyl-sulfoxide-novartis-high-grade-glioma-likelihood-of-approval/ 2025-01-19T18:08:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imetelstat-sodium-geron-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T18:08:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imetelstat-sodium-geron-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T18:09:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fibromun-philogen-melanoma-likelihood-of-approval/ 2025-01-19T18:08:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biomed-x-and-sanofi-begin-joint-research-on-ai-driven-drug-development/ 2023-06-30T16:32:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roctavian-and-biomarins-2-9m-haemophilia-gene-therapy-secures-fda-approval/ 2023-07-05T09:27:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/black-diamond-therapeutics-to-raise-75m-from-public-offering/ 2023-06-30T14:51:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/health-canada-approves-endos-anti-seizure-pills/ 2023-06-30T14:36:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-divest-ophthalmology-assets/ 2023-06-30T14:10:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sangamo-voyager-licence-deal/ 2023-06-30T10:51:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-genenta-glioma-therapy/ 2023-06-30T10:40:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-to-acquire-sigilon/ 2023-06-30T09:08:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-ec-approval-opdivo/ 2023-06-30T08:56:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/baltic-bound-is-lithuania-desirable-for-eu-life-science-investment/ 2023-07-06T14:11:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/inflammatory-bowel-disease-therapies/ 2023-07-06T15:13:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gefurulimab-astrazeneca-net-present-value/ 2024-07-02T02:10:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omalizumab-biosimilar-teva-pharmaceutical-industries-net-present-value/ 2024-07-02T02:10:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-teva-pharmaceutical-industries-net-present-value/ 2024-04-16T17:03:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lysergic-acid-diethylamide-mind-medicine-mindmed-net-present-value/ 2024-05-16T02:07:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muvalaplin-eli-lilly-and-co-net-present-value/ 2024-05-16T01:59:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aflibercept-biosimilar-teva-pharmaceutical-industries-net-present-value/ 2024-07-02T02:10:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gemcitabine-johnson-johnson-net-present-value/ 2024-04-16T16:57:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nisevokitug-novartis-net-present-value/ 2024-04-16T17:03:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/golimumab-biosimilar-teva-pharmaceutical-industries-net-present-value/ 2024-06-13T18:53:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/solbinsiran-sodium-eli-lilly-and-co-net-present-value/ 2024-05-16T01:59:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/batoprotafib-novartis-net-present-value/ 2024-04-16T17:03:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elinzanetant-bayer-net-present-value/ 2024-07-02T02:10:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maplirpacept-pfizer-net-present-value/ 2024-04-16T17:02:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cagrisema-novo-nordisk-net-present-value/ 2024-07-02T02:04:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com701-com902-compugen-net-present-value/ 2024-12-13T02:53:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belrestotug-gsk-net-present-value/ 2024-12-13T02:50:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/apple-makes-a-play-to-change-the-health-metaverse-arena/ 2023-06-29T19:07:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/london-and-west-midlands-lead-uk-fdi-project-charge/ 2023-06-29T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/baltic-bound-is-lithuania-desirable-for-eu-life-science-investment-2/ 2024-03-21T07:22:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/crispr-gene-editing-on-human-embryos-may-have-dangerous-consequences-says-new-study/ 2023-06-29T16:23:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-rejects-alvotech-humira-biosimilar-third-time/ 2023-06-29T16:21:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazenecas-stride-shows-improved-outcomes-for-liver-cancer-patients/ 2023-06-29T16:20:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lantidra-wins-fda-approval-as-first-ever-type-1-diabetes-cell-therapy/ 2023-06-29T15:52:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tevogen-to-go-public-in-1-2bn-spac-deal/ 2023-06-29T15:20:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/interviews/drug-shortages-qa-how-can-the-us-maintain-access-to-essential-drugs/ 2023-07-06T08:14:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/genprexs-reqorsa-fda-fast-track-designation/ 2023-07-05T09:27:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/is-esg-investing-a-redundant-concept/ 2023-06-28T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/brazil-is-leading-the-charge-in-south-america-dedollarisation/ 2023-06-28T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizers-ngenla-fda-approval/ 2023-06-28T16:41:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cellusion-shares-pipeline-update-for-eye-disease-stem-cell-therapy/ 2023-06-28T15:49:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/promising-role-glp-1ras-nash/ 2023-06-28T14:33:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-israel-and-turkey-are-growing-markets-for-clinical-trials/ 2025-07-16T10:56:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/centogene-and-lifera-team-up-for-genetic-testing-service-in-saudi-arabia/ 2023-06-28T14:02:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/esg-in-pharma-meeting-increasing-requirements-in-the-nordic-region/ 2024-01-29T16:50:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sk-bioscience-doherty-influenza/ 2023-06-28T13:06:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/lula-aims-to-establish-brazil-as-pharmaceutical-bellwether-to-south-america/ 2023-06-28T13:06:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/pharma-manufacturing-h1-2023-cmo/ 2023-06-28T10:35:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/australia-specialised-therapeutics-lymphoma/ 2023-06-28T10:39:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-gsk-gonorrhoea-vaccine/ 2023-06-28T10:38:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/medical-cannabis-nhs-uk-prescription-care/ 2024-03-20T03:34:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-xigduo-china-diabetes/ 2023-06-28T08:08:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/xentria-meitheal-licensing-deal/ 2023-06-28T08:07:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/ai-for-patients-hype-or-hope/ 2023-06-29T15:30:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lisata-shares-pipeline-update-of-anticancer-lead-candidate-drug/ 2023-06-28T10:47:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-haemophilia-b-gene-therapy-fda-application/ 2023-06-27T15:58:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/rystiggo-fda-approval-ucbs-myasthenia-gravis/ 2023-06-27T15:15:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/wane-in-covid-demand-hurts-walgreens-as-profits-drop-to-118m/ 2023-06-27T14:52:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-astrazeneca-soliris/ 2023-06-27T14:23:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/inflation-reduction-biologic-drug-venture/ 2023-06-30T09:13:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-approval-shingles-vaccine/ 2023-06-27T10:26:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tonix-to-acquire-migraine-products/ 2023-06-27T10:29:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-approves-bms-camzyos/ 2023-06-27T08:46:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vertex-lonza-cell-therapy/ 2023-07-03T17:02:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/comment/sdgs-role-of-diplomacy-in-achieving-the-sustainable-development-goals/ 2023-06-26T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/janssen-seeks-ema-approval-for-single-tablet-pulmonary-arterial-hypertension-treatment/ 2024-01-23T10:06:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-shelves-one-oral-pill-pivots-to-another-in-weight-loss-drug-race/ 2023-06-26T18:48:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/advancing-gene-modified-cell-therapies/ 2023-07-10T10:07:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-first-ever-adolescent-alopecia-treatment-from-pfizer/ 2023-06-26T16:31:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/boehringer-zealand-obesity-market-positive-phase-ii-data/ 2023-07-03T13:36:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/inova-mundipharma-healthcare/ 2023-06-26T14:16:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/healthcares-digital-transformation-improving-public-trust-with-data-sharing/ 2023-06-28T15:53:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-lung-cancer-screening/ 2023-06-26T10:28:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cmp-pharma-suspension-cholesterol/ 2023-06-26T10:30:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/shionogi-to-acquire-qpex/ 2023-06-26T08:33:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-sciences-trodelvy-chmp/ 2023-06-26T08:04:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/nash-drugs-race-to-cross-the-finish-line/ 2023-06-29T16:02:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/fdi-nigeria-investment-africa-oil-gas-diversification/ 2023-06-25T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvies-migraine-medication-qulipta-gets-positive-chmp-opinion/ 2023-06-23T17:01:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/intercept-winds-down-nash-programme-after-fda-pulls-plug-on-ocaliva/ 2023-06-23T15:55:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/msd-extends-peptide-collaboration-with-irbm/ 2023-06-23T15:35:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-duchenne-gene-therapy-with-hefty-3-2m-price-tag/ 2023-07-04T05:26:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nephrodi-therapeutics-and-msrd-partner-to-develop-therapy-for-ndi/ 2023-06-23T14:21:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/bms-eurofins-andhra-pradesh-and-telangana/ 2023-06-23T14:00:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-can-cdmos-keep-up-with-evolving-compliance/ 2024-03-13T17:16:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/erasca-eras-801-fda-orphan-drug/ 2023-06-23T10:14:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/talaris-therapeutics-tourmaline-bio/ 2023-06-23T10:00:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/kymeras-novel-mdm2-degrader-granted-orphan-designation-for-aml/ 2023-06-23T08:17:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/psylo-daiichi-sankyo-psychiatric-therapies/ 2023-06-23T07:47:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aslan-zenyaku-kogyo-eblasakimab/ 2023-06-23T08:41:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cdc-backs-gsk-and-pfizer-vaccines-to-bring-rsv-protection-one-step-closer/ 2023-06-22T16:56:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/olema-oncology-traces-pivotal-trial-pathway-after-business-challenges/ 2023-06-22T16:55:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/glp-1ra-pilot-scheme-obesity-uk/ 2023-06-22T16:04:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/software-as-a-medical-device-why-companion-apps-are-a-growing-medtech-trend/ 2023-06-29T13:36:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amgen-secures-full-fda-approval-for-leukaemia-therapy-blincyto/ 2023-07-05T16:27:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lilly-boehringer-type-2-diabetes/ 2023-06-22T14:03:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sfda-amarin-vascepa-cardiovascular/ 2023-06-22T10:15:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/advanz-pharma-veeva-systems-digital/ 2023-06-22T10:04:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ultragenyx-gene-therapy-plant/ 2023-06-22T08:55:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/calliditas-snda-fda-tarpeyo/ 2023-06-22T08:55:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/can-vouchers-incentivise-antimicrobial-drug-discovery-in-europe/ 2023-06-21T23:44:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/what-legacy-has-the-world-cup-left-on-qatar-fdi-journey/ 2023-06-21T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/empress-therapeutics-emerges-with-50m-to-fund-small-molecule-development/ 2023-06-21T18:06:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/teikoku-pharma-bags-fda-fast-track-for-post-surgical-transdermal-analgesic/ 2023-06-21T18:02:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-grants-access-to-new-class-of-paediatric-diabetes-medicine/ 2023-06-21T16:46:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/csl-first-patient-hemgenix-haemophilia-b/ 2023-06-21T15:21:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/agepha-pharma-lodoco-fda/ 2023-06-21T13:38:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/coya-therapeutics-coya-301-patent/ 2023-06-21T10:41:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-pfizer-talzenna-xtandi/ 2023-06-21T10:42:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dcgi-gennovas-covid-19-booster/ 2023-06-21T13:52:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/bacterial-infection-key-event-endometriosis/ 2023-06-30T06:14:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pharmather-vitruvias-ketarx-us/ 2023-06-21T08:54:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/why-the-us-1bn-embassy-in-lebanon-is-drawing-praise-and-criticism/ 2023-06-20T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lilly-makes-ambitious-immunology-play-in-2-4bn-dice-therapeutics-acquisition/ 2023-06-21T08:48:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eu-pharma-trade-body-starts-genomic-profiling-initiative-to-improve-access/ 2023-06-20T15:57:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/england-joins-wales-and-scotland-in-halving-hpv-vaccine-dose/ 2023-06-20T15:52:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/argenx-enrols-new-cohort-in-phase-ii-multifocal-motor-neuropathy-study/ 2023-06-20T15:15:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lallemand-health-probiokid-brazil/ 2023-06-20T14:11:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-case-for-ai-and-machine-learning-in-life-sciences/ 2023-07-18T08:20:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/catalyst-santhera-vamorolone/ 2023-06-20T10:29:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/doh-m42-abbvie-medicines/ 2023-06-20T10:23:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/f2g-plans-resubmission-after-fda-rejects-olorofim-nda/ 2023-06-20T08:02:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/university-melbourne-aiid/ 2023-06-20T08:46:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/who-sk-bioscience-skycovione/ 2023-06-20T08:47:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/countries-women-business-political-leadership-positions/ 2023-06-19T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/rosemont-expands-liquid-medicine-portfolio-lucis-acquisition/ 2023-06-19T15:37:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-extends-review-of-gsks-myelofibrosis-drug/ 2023-06-19T15:17:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chinese-authority-medivir-fostrox/ 2023-06-19T15:11:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/why-demand-is-rising-for-secure-and-climate-controlled-gene-therapy-services/ 2025-07-03T10:32:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/overcoming-regulatory-issues-with-investigational-medicinal-product-labelling/ 2024-02-06T12:09:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/laurus-labs-iit-kanpur-gene-therapy/ 2023-06-21T13:50:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bio-thera-biomm-ustekinumab-biosimilar/ 2023-06-19T10:18:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/coherus-biosciences-surface-oncology/ 2023-06-19T08:12:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cholesgen-astrazeneca-advance-research-hypercholesterolemia/ 2023-07-26T04:54:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/the-fdi-landscape-in-the-dominican-republic-in-2023/ 2023-06-18T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tessa-therapeutics-hodgkins-lymphoma-car-t-therapy-shows-promising-phase-i-data/ 2023-06-16T17:17:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aneurotech-shares-plans-for-major-depressive-disorder-pivotal-programme/ 2023-06-16T16:43:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/msds-keytruda-use-in-adenocarcinoma-could-be-limited-based-on-biomarker/ 2023-06-19T10:10:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/race-for-universal-flu-vaccine-osivax/ 2023-06-16T18:15:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/avenge-bio-fda-mesothelioma/ 2023-06-16T13:23:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/flamingo-vlaio-rna-focused/ 2023-06-16T11:42:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-biostar-utidelone-injectable-nsclc/ 2023-06-16T09:50:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abu-dhabi-doh-life-sciences/ 2023-06-16T10:09:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/verix-ai-start-up-ai-acquisition/ 2023-06-16T10:06:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-genentech-columvi-r-r-dlbcl/ 2023-06-16T08:47:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vbi-prehevbri-hepatitis-b-vaccine-uk/ 2023-06-16T07:06:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sandoz-targets-barriers-to-biosimilar-accessibility-with-latest-initiative/ 2023-06-15T16:33:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eloxx-repackages-elx-02-data-in-cystic-fibrosis-as-it-eyes-pivotal-trial/ 2023-07-19T04:45:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astellas-cullgen-small-molecule-protein-degraders/ 2023-06-15T15:08:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/verve-therapeutics-lilly-gene-editing/ 2023-06-21T13:52:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/confo-therapeutics-abcellera-antibodies/ 2023-06-15T13:32:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/efficiency-meets-energy-savings-a-new-generation-of-hepa-filters/ 2023-10-26T12:58:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/effizienz-trifft-auf-energieeinsparung-eine-neue-generation-von-hepa-filtern/ 2023-10-24T11:56:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/streamlining-healthcare-with-ai-for-drug-development/ 2023-08-08T08:10:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-using-ai-in-clinical-trials-accelerates-drug-development/ 2023-08-08T08:10:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-potential-of-ai-in-pharma-rd/ 2023-08-08T08:07:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-ipsen-metastatic-pdac/ 2023-06-15T10:54:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-amneal-nda-pemrydi-rtu/ 2023-06-15T10:45:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chugai-nda-crovalimab-japan/ 2023-06-15T08:32:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-alentis-ale-c04-cldn1-tumours/ 2023-06-15T08:34:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/what-are-the-global-trends-for-fdi-in-ai/ 2023-06-14T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/blue-water-biotech-shores-up-portfolio-with-purchase-of-six-fda-approved-treatments/ 2023-06-14T16:37:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eu-authority-adopts-recommendations-to-boost-fight-against-amr-by-2030/ 2023-06-14T16:57:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/pangenome-personalised-medicine/ 2023-06-14T15:14:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-qidp-fast-track-eagle-cal02/ 2023-06-14T13:17:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/epo-vistagen-ph80-nasal-spray/ 2023-06-14T13:06:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/a-winning-combination-the-benefits-of-micronization-and-containment-in-a-single-installation/ 2023-06-14T11:16:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ipsen-bylvay-fda-cholestatic-pruritus/ 2023-06-14T10:27:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-nmpa-astrazeneca-soliris/ 2023-06-14T09:57:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/develop-and-execute-a-winning-drug-launch-strategy-with-an-experienced-contract-packager/ 2025-07-03T10:40:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-fast-track-cellcentric-inobrodib/ 2023-06-14T08:04:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/senju-novaliq-agreement-dry-eye/ 2023-06-14T08:43:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/beacon-therapeutics-enters-gene-therapy-arena-with-120m-launch/ 2023-06-14T16:07:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-gives-ferring-go-ahead-for-adstiladrin-gene-therapy-manufacturing/ 2023-06-14T16:07:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uspto-windtree-serca2a-activators/ 2023-06-13T13:13:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-ironwood-pharmaceuticals-linzess/ 2023-06-13T13:01:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/idorsia-quviviq-switzerland-insomnia/ 2023-06-13T10:37:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-nordisk-2-3bn-manufacturing-facilities/ 2023-06-13T10:34:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/eha-2023-kura-menin-ziftomenib/ 2023-06-13T10:08:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/pricing-and-market-access/snap-spanish-election-health/ 2023-06-13T08:34:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-neobiosis-post-covid-syndrome/ 2023-06-13T09:34:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-astrazeneca-breast-cancer/ 2023-06-13T07:17:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cloud-mentions-pharmaceutical-industry/ 2024-07-18T14:38:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/filings/internet-of-things-mentions-pharmaceutical-industry/ 2024-04-30T02:38:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/the-uk-has-lost-nearly-200000-manufacturing-jobs-since-2010/ 2023-06-12T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-greenlights-first-otc-topical-gel-for-erectile-dysfunction/ 2023-06-12T17:09:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biogen-and-eisais-alzheimers-drug-secures-support-in-closely-watched-adcom/ 2023-06-12T14:53:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lotus-pharmaceuticals-teraju-products/ 2023-06-12T14:40:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eccogene-metabolic-pipeline-development/ 2023-06-12T14:08:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-milla-pharmaceuticals-precedex/ 2023-06-12T10:33:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/quell-astrazenecar-treg-cell-therapies/ 2023-06-12T10:33:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/cannabinoids-solution-opioid/ 2023-06-12T08:01:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-buy-chinook-therapeutics/ 2023-06-12T07:54:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astellas-pharma-zolbetuximab-japan/ 2023-06-12T07:50:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/how-is-climate-change-risk-affecting-fdi-inflows/ 2023-06-11T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emicizumab-chugai-pharmaceutical-acquired-hemophilia-a-likelihood-of-approval/ 2023-06-10T12:58:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bermekimab-xbiotech-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-19T17:42:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navtemadlin-kartos-therapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T17:42:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ziftomenib-kura-oncology-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T17:42:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ziftomenib-kura-oncology-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T17:42:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erenumab-amgen-pain-likelihood-of-approval/ 2024-06-14T01:47:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tominersen-f-hoffmann-la-roche-huntington-disease-likelihood-of-approval/ 2023-06-10T12:55:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-activate-cxcr4-for-hiv-sangamo-therapeutics-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-04-19T01:27:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clv-100-cytopeutics-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2023-06-10T12:55:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selinexor-karyopharm-therapeutics-peripheral-nerve-sheath-tumor-neurofibrosarcoma-likelihood-of-approval/ 2025-01-19T17:42:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mbf-015-medibiofarma-huntington-disease-likelihood-of-approval/ 2025-01-19T18:04:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qls-111-qlaris-bio-ocular-hypertension-likelihood-of-approval/ 2025-01-19T18:08:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qls-111-qlaris-bio-open-angle-glaucoma-likelihood-of-approval/ 2025-01-19T18:08:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vtx-2735-ventyx-biosciences-familial-cold-autoinflammatory-syndrome-familial-cold-urticaria-likelihood-of-approval/ 2025-01-19T18:04:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mytx-011-mythic-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T02:04:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mt-101-mthera-pharma-parkinson-s-disease-likelihood-of-approval/ 2024-01-24T18:37:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-1908-legend-biotech-gastric-cancer-likelihood-of-approval/ 2024-07-05T05:46:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-1908-legend-biotech-esophageal-cancer-likelihood-of-approval/ 2024-07-05T05:46:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-1908-legend-biotech-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-07-05T05:46:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mw-032-mabwell-shanghai-bioscience-bone-metastasis-likelihood-of-approval/ 2024-04-19T16:22:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-2265-fusion-pharmaceuticals-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-19T18:06:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oxymetazoline-levation-pharma-ptosis-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eumcv5-eubiologics-neisseria-meningitidis-infections-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tl-925-telios-pharma-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2024-04-19T16:26:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onureg-bristol-myers-squibb-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T18:03:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onureg-bristol-myers-squibb-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T18:03:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ro-7308480-f-hoffmann-la-roche-social-anxiety-disorder-sad-social-phobia-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ckr-051-ck-regeon-diabetic-foot-ulcers-likelihood-of-approval/ 2024-07-05T05:44:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ckr-051-ck-regeon-alopecia-likelihood-of-approval/ 2024-07-05T05:44:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ckr-051-ck-regeon-wounds-likelihood-of-approval/ 2024-07-05T05:45:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivxa-12-icosavax-human-metapneumovirus-infections-likelihood-of-approval/ 2023-07-01T01:27:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bcd-245-biocad-neuroblastoma-likelihood-of-approval/ 2025-01-19T18:03:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vyn-201-vyne-therapeutics-vitiligo-likelihood-of-approval/ 2025-01-19T18:04:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fbta-05-lindis-biotech-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T02:04:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/h3-mrna-lnp-vaccine-sanofi-influenza-a-virus-h3n2-subtype-infections-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-2618-chia-tai-tianqing-pharmaceutical-group-nasopharyngeal-cancer-likelihood-of-approval/ 2025-01-19T18:03:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vh-4004280-viiv-healthcare-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-04-19T16:23:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1011-1-moderna-seasonal-influenza-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1011-2-moderna-seasonal-influenza-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1012-1-moderna-seasonal-influenza-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bx-004-biomx-resistant-pseudomonas-aeruginosa-infections-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-4703-johnson-johnson-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-01-08T19:13:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vhx-896-vanda-pharmaceuticals-schizophrenia-likelihood-of-approval/ 2025-01-19T18:05:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1083-moderna-influenza-a-virus-h1n1-subtype-infections-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1083-moderna-influenzavirus-b-infections-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-quavonlimab-merck-melanoma-likelihood-of-approval/ 2025-01-19T18:05:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1083-moderna-influenza-a-virus-h3n2-subtype-infections-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/br-1018-boryung-pharmaceutical-idiopathic-essential-hypertension-likelihood-of-approval/ 2024-04-19T16:25:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alnttrsc-04-alnylam-pharmaceuticals-amyloidosis-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ucb-7853-ucb-parkinson-s-disease-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/m-9140-merck-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-19T18:06:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-16673-beigene-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:05:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-16673-beigene-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2025-01-19T18:05:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vb-119-acelyrin-focal-segmental-glomerulosclerosis-fsgs-likelihood-of-approval/ 2024-04-20T04:57:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-16673-beigene-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:05:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tin-816-novartis-sepsis-likelihood-of-approval/ 2025-01-19T18:06:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-319-abbvie-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:06:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-319-abbvie-follicular-lymphoma-likelihood-of-approval/ 2025-01-19T18:06:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-319-abbvie-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:07:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-319-abbvie-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:07:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aphd-012-aphaia-pharma-pre-diabetes-impaired-glucose-tolerance-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07831694-pfizer-clostridioides-difficile-infections-clostridium-difficile-associated-disease-likelihood-of-approval/ 2024-06-20T15:19:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vx-973-vertex-pharmaceuticals-pain-likelihood-of-approval/ 2024-02-21T23:46:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amitriptyline-hydrochloride-algotherapeutix-erythromelalgia-likelihood-of-approval/ 2025-01-19T18:02:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/e-2086-eisai-narcolepsy-likelihood-of-approval/ 2025-01-19T18:07:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bay-2927088-bayer-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:05:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cardix-101-what-is-the-likelihood-that-drug-will-be-approved/ 2023-08-10T17:10:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jcxh-105-immorna-hangzhou-biotechnology-herpes-zoster-shingles-likelihood-of-approval/ 2025-01-19T18:07:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rmc-6236-revolution-medicines-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T16:53:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vk-2735-viking-therapeutics-obesity-likelihood-of-approval/ 2025-01-19T16:36:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lasn-01-lassen-therapeutics-1-graves-ophthalmopathy-likelihood-of-approval/ 2024-06-14T01:56:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-8630-astrazeneca-asthma-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nc-525-nextcure-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-04-19T16:24:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nc-525-nextcure-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-04-19T16:24:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jd-010-beijing-jd-biotech-hematological-tumor-likelihood-of-approval/ 2024-01-08T19:14:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ptc-607-ptc-therapeutics-huntington-disease-likelihood-of-approval/ 2023-06-09T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-765423-boehringer-ingelheim-international-pulmonary-fibrosis-likelihood-of-approval/ 2024-04-19T16:26:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvd-003-novadip-biosciences-pseudarthrosis-nonunion-of-fracture-pseudoarthrosis-likelihood-of-approval/ 2024-05-20T02:17:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/prescription-drug-costs-for-nhs-in-england-rise-by-8-to-10-4bn/ 2023-06-09T17:45:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-committee-recommends-astrazeneca-and-sanofis-rsv-prophylactic-nirsevimab/ 2023-06-09T16:56:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novaliq-dry-eye-disease-therapy/ 2023-06-09T14:36:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/upstream-bio-clinical-development-upb-101/ 2023-06-09T13:35:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bristol-myers-squibb-fda-approval/ 2023-06-14T16:25:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-eua-covid-19-vaccine/ 2023-06-09T10:17:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/clinical-data-consent-management-challenges/ 2023-12-14T12:16:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/jobs/hiring-asia-pacific-pharma-industry-q1-2023/ 2023-06-09T07:44:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/rocket-pharmaceuticals-rp-a601-fda/ 2023-06-14T16:08:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astellas-pharma-kate-kt430/ 2023-06-09T07:13:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbl-514-caliway-biopharmaceutics-cellulite-likelihood-of-approval/ 2025-01-19T17:50:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lotilaner-tarsus-pharmaceuticals-meibomian-blepharitis-likelihood-of-approval/ 2024-03-18T18:18:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bl-001-bloom-science-epilepsy-likelihood-of-approval/ 2023-06-08T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bl-001-bloom-science-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2023-06-08T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/encaleret-bridgebio-pharma-autosomal-dominant-hypocalcemia-likelihood-of-approval/ 2023-06-08T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/povorcitinib-phosphate-incyte-vitiligo-likelihood-of-approval/ 2025-01-19T17:50:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-164-biontech-tuberculosis-likelihood-of-approval/ 2024-04-19T16:15:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/povetacicept-alpine-immune-sciences-iga-nephropathy-berger-s-disease-likelihood-of-approval/ 2025-01-19T18:02:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/meropenem-vaborbactam-melinta-therapeutics-bacterial-infections-likelihood-of-approval/ 2024-02-21T23:54:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/impt-314-immpact-bio-usa-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:01:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/impt-314-immpact-bio-usa-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:01:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mirikizumab-eli-lilly-and-co-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2025-01-19T17:43:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/empasiprubart-argenx-dermatomyositis-likelihood-of-approval/ 2025-01-19T17:43:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tigilanol-tiglate-qbiotics-group-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-19T17:43:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/testosterone-tridecanoate-lipocine-sarcopenia-likelihood-of-approval/ 2024-05-20T02:16:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bay-2416964-bayer-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-14T01:15:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensomafusp-alfa-f-hoffmann-la-roche-follicular-lymphoma-likelihood-of-approval/ 2025-01-19T18:01:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-b-cell-chronic-lymphocytic-leukemia-likelihood-of-approval/ 2025-01-19T18:01:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snipr-001-snipr-biome-escherichia-coli-infections-likelihood-of-approval/ 2025-01-19T18:01:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vartocell-what-is-the-likelihood-that-drug-will-be-approved/ 2023-08-10T17:10:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/levetiracetam-er-agenebio-mild-cognitive-impairment-likelihood-of-approval/ 2024-02-08T03:07:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-3804-chia-tai-tianqing-pharmaceutical-group-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:01:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disc-0974-disc-medicine-anemia-in-chronic-kidney-disease-renal-anemia-likelihood-of-approval/ 2025-01-19T18:02:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osimertinib-mesylate-astrazeneca-non-small-cell-lung-carcinoma-likelihood-of-approval/ 2025-01-19T17:43:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegtibatinase-travere-therapeutics-homocystinuria-likelihood-of-approval/ 2024-07-05T05:10:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/poly-iclc-oncovir-prostate-cancer-likelihood-of-approval/ 2025-01-19T17:43:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ksi-501-kodiak-sciences-diabetic-macular-edema-likelihood-of-approval/ 2025-01-19T17:50:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irl-201104-revolo-biotherapeutics-allergies-likelihood-of-approval/ 2025-01-19T17:43:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irl-201104-revolo-biotherapeutics-seasonal-allergic-rhinitis-likelihood-of-approval/ 2025-01-19T17:43:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mibavademab-regeneron-pharmaceuticals-congenital-generalized-lipodystrophy-berardinelli-seip-syndrome-likelihood-of-approval/ 2025-01-19T17:50:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mibavademab-regeneron-pharmaceuticals-acquired-generalized-lipodystrophy-lawrence-syndrome-likelihood-of-approval/ 2025-01-19T17:50:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-19T17:50:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vyznova-aurion-biotechnologies-corneal-edema-likelihood-of-approval/ 2025-01-19T18:02:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/melatonin-repoceuticals-radiodermatitis-likelihood-of-approval/ 2025-01-19T16:36:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/4dmts-cf-gene-therapy-posts-early-cues-for-improving-patient-outcomes/ 2023-07-31T07:10:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gritstone-bio-supports-mrna-covid-19-vaccine-plans-with-phase-i-publication/ 2023-06-08T16:29:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/genscript-probio-ccs-cell-gene-therapies/ 2023-06-14T16:09:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-merz-therapeutics-xeomin/ 2023-06-08T11:23:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mendus-northx-establish-manufacturing/ 2023-06-14T16:09:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-orphan-drug-dtx-pharmas-cmt1a/ 2023-06-08T10:46:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-rise-and-rise-of-esg-in-the-pharmaceutical-sector-is-a-zero-waste-supply-chain-possible/ 2023-07-31T15:47:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/why-data-management-and-decision-making-go-hand-in-hand-in-clinical-research/ 2023-06-13T14:41:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-gsks-rsv-vaccine-arexvy/ 2023-06-08T09:37:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/hopewell-therapeutics-genomic-medicines/ 2023-06-08T09:38:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/deal-of-the-week-strive-health-raises-166m-to-aid-kidney-health-services/ 2023-06-08T12:33:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbx-12-cybrexa-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:01:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0780-astrazeneca-cardiovascular-disease-likelihood-of-approval/ 2025-01-19T18:01:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voruciclib-mei-pharma-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-06-14T01:43:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voruciclib-mei-pharma-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-06-14T01:43:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obexelimab-zenas-biopharma-usa-immunoglobulin-g4-related-disease-igg4-rd-likelihood-of-approval/ 2025-01-19T17:24:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pridopidine-hydrochloride-prilenia-therapeutics-development-huntington-disease-likelihood-of-approval/ 2023-09-15T00:12:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gimatecan-lee-s-pharmaceutical-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-09-09T01:55:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apalutamide-johnson-johnson-salivary-gland-cancer-likelihood-of-approval/ 2025-01-19T17:25:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-f-hoffmann-la-roche-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T17:25:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-biogen-post-transplant-lymphoproliferative-disorder-likelihood-of-approval/ 2025-01-19T17:25:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vatiquinone-ptc-therapeutics-friedreich-ataxia-likelihood-of-approval/ 2025-01-19T17:26:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vatiquinone-ptc-therapeutics-subacute-necrotizing-encephalomyelopathy-leigh-disease-likelihood-of-approval/ 2025-01-19T17:26:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnc-210-bionomics-post-traumatic-stress-disorder-ptsd-likelihood-of-approval/ 2025-01-19T17:41:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizanlizumab-novartis-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2023-06-07T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vatiquinone-ptc-therapeutics-melas-syndrome-mitochondrial-encephalomyopathy-lactic-acidosis-and-stroke-like-episodes-likelihood-of-approval/ 2025-01-19T17:26:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnc-210-bionomics-social-anxiety-disorder-sad-social-phobia-likelihood-of-approval/ 2025-01-19T17:41:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bitopertin-disc-medicine-porphyria-erythropoietic-protoporphyri-likelihood-of-approval/ 2024-09-09T01:55:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iltamiocel-cook-myosite-fecal-incontinence-likelihood-of-approval/ 2025-01-19T17:41:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tradipitant-vanda-pharmaceuticals-motion-sickness-likelihood-of-approval/ 2025-01-19T17:25:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisagenlecleucel-novartis-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T17:24:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/famitinib-jiangsu-hengrui-medicine-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-09-09T01:56:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-19T17:41:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-19T17:41:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apatinib-mesylate-elevar-therapeutics-melanoma-likelihood-of-approval/ 2025-01-19T17:24:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apatinib-mesylate-elevar-therapeutics-synovial-sarcoma-likelihood-of-approval/ 2025-01-19T17:24:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-124e-immuron-traveler-s-diarrhea-likelihood-of-approval/ 2023-06-07T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpa-150-five-prime-therapeutics-epithelial-ovarian-cancer-likelihood-of-approval/ 2023-06-07T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opk-88005-opko-health-hemophilia-a-factor-viii-deficiency-likelihood-of-approval/ 2025-01-19T17:41:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opk-88005-opko-health-hemophilia-b-factor-ix-deficiency-likelihood-of-approval/ 2025-01-19T17:41:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teverelix-antev-metastatic-prostate-cancer-likelihood-of-approval/ 2024-06-14T01:43:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teverelix-antev-hormone-sensitive-prostate-cancer-likelihood-of-approval/ 2024-06-14T01:43:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lufepirsen-amber-ophthalmics-persistent-corneal-epithelial-defects-likelihood-of-approval/ 2023-08-28T04:30:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esaxerenone-daiichi-sankyo-diabetic-hypertension-likelihood-of-approval/ 2023-06-07T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T16:36:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-ends-phase-iv-andexxa-trial-after-positive-results/ 2023-06-07T16:57:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eu-agencies-back-covid-19-vaccine-update-ahead-of-autumn-campaign/ 2023-06-07T16:17:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/baudax-bio-reports-promising-additional-data-for-neuromuscular-blockade-agent/ 2023-06-07T15:49:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/zyversa-european-patent-var-200/ 2023-06-07T13:34:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fosun-pharma-ifc-drug-manufacturing/ 2023-06-07T12:30:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/new-dna-extraction-method-for-long-read-sequencing-in-plant-tissues-at-the-university-of-illinois/ 2024-02-28T10:37:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-gsk-jemperli-endometrial/ 2023-06-07T10:24:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/acepodia-advance-cell-therapies/ 2023-06-14T16:06:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/eli-lilly-obesity/ 2023-06-07T09:42:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-merck-prevymis-letermovir/ 2023-06-07T07:40:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-marketing-fennec-pedmarqsi/ 2023-06-07T08:30:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agn-193408-sr-abbvie-ocular-hypertension-likelihood-of-approval/ 2024-04-19T01:13:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agn-193408-sr-abbvie-open-angle-glaucoma-likelihood-of-approval/ 2024-04-19T01:13:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tdm-105795-technoderma-medicines-androgenic-alopecia-likelihood-of-approval/ 2023-06-06T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tdm-180935-technoderma-medicines-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-19T17:21:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chlorthalidone-losartan-laboratorios-silanes-idiopathic-essential-hypertension-likelihood-of-approval/ 2023-06-06T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shj-002-sunhawk-vision-biotech-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2023-06-06T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caficrestat-applied-therapeutics-cardiomyopathy-likelihood-of-approval/ 2023-06-06T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isatuximab-sanofi-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-19T17:23:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isatuximab-sanofi-natural-killer-cell-lymphomas-likelihood-of-approval/ 2025-01-19T17:23:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guadecitabine-sodium-astex-pharmaceuticals-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T17:20:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobimetinib-fumarate-f-hoffmann-la-roche-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T17:22:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobimetinib-fumarate-f-hoffmann-la-roche-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T17:22:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobimetinib-fumarate-f-hoffmann-la-roche-craniopharyngioma-likelihood-of-approval/ 2025-01-19T17:22:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itolizumab-equillium-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-19T17:22:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aglatimagene-besadenovec-candel-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T17:19:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alimta-eli-lilly-and-co-chordoma-likelihood-of-approval/ 2023-06-06T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rifamycin-sodium-cr-cosmo-pharmaceuticals-hepatic-encephalopathy-likelihood-of-approval/ 2025-01-19T17:23:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/everolimus-novartis-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-19T17:23:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ramucirumab-eli-lilly-and-co-thymic-carcinoma-likelihood-of-approval/ 2025-01-19T17:23:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adavosertib-astrazeneca-cervical-cancer-likelihood-of-approval/ 2025-01-19T18:24:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adavosertib-astrazeneca-vaginal-cancer-likelihood-of-approval/ 2025-01-19T18:24:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evx-02-evaxion-biotech-melanoma-likelihood-of-approval/ 2023-06-06T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrg-002-shanghai-miracogen-bladder-cancer-likelihood-of-approval/ 2025-01-19T17:21:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eli-002-elicio-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T16:52:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venglustat-malate-sanofi-gaucher-disease-type-iii-likelihood-of-approval/ 2023-06-06T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pelareorep-oncolytics-biotech-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T17:23:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexanolone-sage-therapeutics-tinnitus-likelihood-of-approval/ 2024-02-08T02:51:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trametinib-dimethyl-sulfoxide-novartis-hairy-cell-leukemia-likelihood-of-approval/ 2025-01-19T17:21:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eltrombopag-olamine-novartis-fanconi-anemia-likelihood-of-approval/ 2024-01-08T18:16:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rapcabtagene-autoleucel-novartis-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-19T18:00:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rapcabtagene-autoleucel-novartis-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:00:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rapcabtagene-autoleucel-novartis-lupus-nephritis-likelihood-of-approval/ 2025-01-19T18:00:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rapcabtagene-autoleucel-novartis-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:00:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rapcabtagene-autoleucel-novartis-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:00:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-ipsen-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-19T17:23:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bizalimogene-ralaplasmid-mavilimogene-ralaplasmid-inovio-pharmaceuticals-anal-dysplasia-likelihood-of-approval/ 2024-07-05T06:01:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibrutinib-abbvie-primary-cns-lymphoma-likelihood-of-approval/ 2025-01-19T17:21:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gtx-102-ultragenyx-pharmaceutical-angelman-syndrome-likelihood-of-approval/ 2025-01-21T16:52:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asco-2023-ellipses-pharma-advances-plans-for-ret-inhibitor-following-encouraging-results/ 2023-06-06T18:00:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/influencers-dashboards/social-media-posts-big-data-pharma-industry/ 2023-06-06T17:57:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/influencers-dashboards/social-media-posts-microbiome-pharma-industry/ 2023-06-06T17:57:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/influencers-dashboards/social-media-posts-orphan-designated-drugs-pharma-industry/ 2023-06-06T17:57:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/influencers-dashboards/social-media-posts-regenerative-medicine-pharma-industry/ 2023-06-06T17:57:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/influencers-dashboards/social-media-posts-virtual-care-pharma-industry/ 2023-06-06T17:57:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ecubectedin-pharma-mar-net-present-value/ 2024-07-02T02:10:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-06835375-pfizer-net-present-value/ 2024-04-16T17:02:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/remternetug-eli-lilly-and-co-net-present-value/ 2024-05-16T01:59:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/myk-224-bristol-myers-squibb-net-present-value/ 2024-06-13T18:53:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanzalintinib-exelixis-net-present-value/ 2024-06-13T18:53:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegtibatinase-travere-therapeutics-net-present-value/ 2024-06-13T18:49:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olafertinib-fortress-biotech-net-present-value/ 2024-06-13T18:53:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sisunatovir-hydrochloride-pfizer-net-present-value/ 2024-04-16T17:02:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fianlimab-regeneron-pharmaceuticals-net-present-value/ 2024-07-02T02:09:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/doxycycline-hyclate-cr-polypid-net-present-value/ 2024-05-16T02:06:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oric-114-oric-pharmaceuticals-net-present-value/ 2024-06-13T18:53:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opc-1-lineage-cell-therapeutics-net-present-value/ 2024-05-16T02:06:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inclacumab-pfizer-net-present-value/ 2024-05-16T01:59:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rgx-111-regenxbio-net-present-value/ 2024-05-16T02:06:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-06425090-pfizer-net-present-value/ 2024-12-13T02:53:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibezapolstat-acurx-pharmaceuticals-net-present-value/ 2024-05-16T02:07:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vaxequity-uk-grant-rna-manufacturing-cpi/ 2023-06-06T17:10:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asco-2023-moderna-and-msds-personalised-vaccine-reduces-chances-of-melanoma-spreading/ 2023-06-06T18:03:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asco-2023-janssens-carvykti-wins-in-earlier-treatment-of-multiple-myeloma/ 2023-06-06T15:34:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-european-reference-genome-atlas-initiative-advancing-understanding-of-european-biodiversity/ 2024-02-28T10:35:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/oragenics-cqdm-covid-19-vaccine/ 2023-06-06T13:26:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-injectafer-iron-deficiency-heart-failure/ 2023-06-06T13:21:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lotus-nrx-alvogen-nrx-101/ 2023-06-06T10:22:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uspto-enverics-evm301-series/ 2023-06-06T10:07:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/alkeus-stargardt-disease-gildeuretinol/ 2023-06-06T08:20:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/magazine-the-journey-of-first-generics/ 2023-07-06T21:30:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/avadel-excessive-daytime-sleepiness/ 2023-06-06T08:20:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-5528-bicycle-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T17:48:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-5528-bicycle-therapeutics-esophageal-cancer-likelihood-of-approval/ 2025-01-19T17:48:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-ovarian-cancer-likelihood-of-approval/ 2025-01-19T16:36:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bwc-0977-bugworks-research-campylobacter-infections-likelihood-of-approval/ 2024-05-20T02:41:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lyt-200-puretech-health-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-14T01:53:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lyt-200-puretech-health-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-14T01:53:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bentracimab-serb-bleeding-and-clotting-disorders-likelihood-of-approval/ 2025-01-19T17:47:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/granite-001-gritstone-bio-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-06-20T15:19:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutetium-lu-177-vipivotide-tetraxetan-advanced-accelerator-applications-castration-resistant-prostate-cancer-crpc-likelihood-of-approval/ 2025-01-19T17:49:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-110-crispr-therapeutics-follicular-lymphoma-likelihood-of-approval/ 2024-07-05T05:16:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonpiretigene-isteparvovec-nanoscope-therapeutics-juvenile-macular-degeneration-stargardt-disease-likelihood-of-approval/ 2024-06-14T01:52:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vidofludimus-calcium-immunic-primary-progressive-multiple-sclerosis-ppms-likelihood-of-approval/ 2023-07-31T01:04:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anx-007-annexon-geographic-atrophy-likelihood-of-approval/ 2025-01-19T17:47:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-colon-cancer-likelihood-of-approval/ 2025-01-19T17:48:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-19T17:49:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-laryngeal-cancer-likelihood-of-approval/ 2025-01-19T17:49:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jaktinib-hydrochloride-what-is-the-likelihood-that-drug-will-be-approved/ 2023-08-10T17:02:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-nasopharyngeal-cancer-likelihood-of-approval/ 2025-01-19T17:49:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-19T17:49:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-19T17:49:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisaftoclax-ascentage-pharma-group-international-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-19T17:48:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/izalontamab-systimmune-lung-adenocarcinoma-likelihood-of-approval/ 2025-01-19T17:49:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quemliclustat-arcus-biosciences-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T17:49:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/budigalimab-abbvie-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2025-01-19T17:48:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/1928zt-2-wellington-zhaotai-therapies-lymphoma-likelihood-of-approval/ 2025-01-19T17:48:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-biosimilar-innovent-biologics-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2023-07-01T00:58:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vesigel-urogen-pharma-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2023-06-05T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/serclutamab-talirine-abbvie-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-05-20T02:13:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cwt-001-causeway-therapeutics-lateral-epicondylitis-tennis-elbow-likelihood-of-approval/ 2024-06-14T01:53:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senl-b19-hebei-senlang-biotechnology-lymphoma-likelihood-of-approval/ 2024-09-09T02:01:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senl-b19-hebei-senlang-biotechnology-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T02:01:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senl-b19-hebei-senlang-biotechnology-leukemia-likelihood-of-approval/ 2024-09-09T02:01:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venadaparib-idience-gastric-cancer-likelihood-of-approval/ 2024-09-09T02:01:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hymecromone-halo-biosciences-primary-sclerosing-cholangitis-likelihood-of-approval/ 2023-06-05T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hymecromone-halo-biosciences-interstitial-lung-diseases-diffuse-parenchymal-lung-disease-likelihood-of-approval/ 2023-06-05T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ciclopirox-atlas-molecular-pharma-porphyria-erythropoietic-protoporphyri-likelihood-of-approval/ 2023-06-05T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-amgen-male-infertility-likelihood-of-approval/ 2025-01-19T17:19:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/detomidine-clexio-biosciences-pruritus-likelihood-of-approval/ 2025-01-19T17:51:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdtx-1535-black-diamond-therapeutics-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-06-14T01:54:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-merkel-cell-carcinoma-likelihood-of-approval/ 2025-01-19T17:47:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ic9-car-19-bellicum-pharmaceuticals-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T17:48:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avutometinib-potassium-verastem-peritoneal-cancer-likelihood-of-approval/ 2025-01-19T17:19:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pasireotide-what-is-the-likelihood-that-drug-will-be-approved/ 2023-08-10T17:02:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tld-1433-theralase-technologies-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2023-07-31T01:05:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/selvita-university-of-oxford-parkinsons-disease/ 2023-06-05T17:51:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/summit-therapeutics-bispecific-nsclc-asco-202/ 2023-06-05T17:20:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/asco-2023-research-backs-chemo-only-approach-for-some-rectal-cancer-patients/ 2023-06-05T15:37:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/itm-raises-273-million-to-fund-radionuclide-therapy-pipeline/ 2023-06-05T15:23:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etigilimab-mereo-biopharma-group-endometrial-cancer-likelihood-of-approval/ 2024-09-09T02:00:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gemcitabine-johnson-johnson-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2025-01-19T17:47:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mupadolimab-corvus-pharmaceuticals-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T17:46:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rozibafusp-alfa-amgen-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-04-19T01:39:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/load-703-lokon-pharma-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-19T16:35:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/milvexian-bristol-myers-squibb-venous-thromboembolism-likelihood-of-approval/ 2025-01-19T17:46:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spesolimab-boehringer-ingelheim-international-netherton-syndrome-trichorrhexis-invaginata-bamboo-hair-likelihood-of-approval/ 2025-01-19T17:46:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daridorexant-hydrochloride-idorsia-pharmaceutical-post-traumatic-stress-disorder-ptsd-likelihood-of-approval/ 2025-01-19T17:46:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/marstacimab-pfizer-hemophilia-b-factor-ix-deficiency-likelihood-of-approval/ 2025-01-19T17:46:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bintrafusp-alfa-merck-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-19T17:46:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fp-045-foresee-pharmaceuticals-fanconi-anemia-likelihood-of-approval/ 2025-01-19T17:46:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fostroxacitabine-bralpamide-hydrochloride-medivir-hepatocellular-carcinoma-likelihood-of-approval/ 2023-06-05T13:54:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cetuximab-biobetter-shanghai-henlius-biotech-nasopharyngeal-cancer-likelihood-of-approval/ 2025-01-19T17:45:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dtdec-01-dystrogen-therapeutics-duchenne-muscular-dystrophy-likelihood-of-approval/ 2024-07-05T05:19:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ent-001-enthera-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-02-21T22:38:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/okyo-0101-okyo-pharma-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2025-01-19T17:51:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alllife-car-nk-cd19-allife-medical-science-and-technology-b-cell-leukemia-likelihood-of-approval/ 2024-01-24T18:33:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-1005-asklepios-biopharmaceutical-parkinson-s-disease-likelihood-of-approval/ 2025-01-19T17:51:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-3888550a-gsk-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2024-07-05T05:19:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibi-110-innovent-biologics-hepatocellular-carcinoma-likelihood-of-approval/ 2024-07-05T05:18:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ak-otof-akouos-acute-sensorineural-hearing-loss-likelihood-of-approval/ 2023-06-05T13:48:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tafenoquine-succinate-60-degrees-pharmaceuticals-tick-borne-diseases-likelihood-of-approval/ 2025-01-19T18:26:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nipocalimab-johnson-johnson-erythroblastosis-fetalis-hemolytic-disease-in-newborns-likelihood-of-approval/ 2025-01-19T17:45:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/licaminlimab-oculis-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2024-04-19T00:09:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pelacarsen-sodium-novartis-cardiovascular-disease-likelihood-of-approval/ 2024-09-09T04:06:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-19T17:45:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-hormone-sensitive-prostate-cancer-likelihood-of-approval/ 2025-01-19T17:45:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arct-810-arcturus-therapeutics-ornithine-transcarbamylase-deficiency-likelihood-of-approval/ 2025-01-19T17:45:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alxn-2220-alexion-pharmaceuticals-familial-amyloid-cardiomyopathy-likelihood-of-approval/ 2024-06-14T01:50:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jcar-014-bristol-myers-squibb-mantle-cell-lymphoma-likelihood-of-approval/ 2024-05-20T02:09:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zelpultide-alfa-airway-therapeutics-bronchopulmonary-dysplasia-likelihood-of-approval/ 2023-06-05T13:39:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/odronextamab-regeneron-pharmaceuticals-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-19T17:44:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/odronextamab-regeneron-pharmaceuticals-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T17:44:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegcetacoplan-apellis-pharmaceuticals-membranoproliferative-glomerulonephritis-mesangiocapillary-glomerulonephritis-likelihood-of-approval/ 2025-01-19T17:44:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-ceruvia-lifesciences-smoking-cessation-likelihood-of-approval/ 2025-01-19T17:44:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/otl-203-orchard-therapeutics-mucopolysaccharidosis-i-mps-i-hurler-syndrome-likelihood-of-approval/ 2024-01-08T18:56:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zifanocycline-kbp-biosciences-skin-and-skin-structure-infections-sssi-caused-by-bacteria-likelihood-of-approval/ 2024-06-14T01:49:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zifanocycline-kbp-biosciences-community-acquired-bacterial-pneumonia-likelihood-of-approval/ 2024-06-14T01:49:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onl-1204-onl-therapeutics-retinal-pigment-epithelial-rpe-detachment-likelihood-of-approval/ 2025-01-19T17:44:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cefepime-enmetazobactam-allecra-therapeutics-urinary-tract-infections-likelihood-of-approval/ 2024-02-22T00:07:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirolimus-what-is-the-likelihood-that-drug-will-be-approved/ 2023-08-10T17:00:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cilostazol-cr-genovate-biotechnology-intermittent-claudication-likelihood-of-approval/ 2023-07-01T00:47:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uhn-providence-mrna-cancer/ 2023-06-07T10:07:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/interviews/qa-how-big-pharma-implements-analytics-in-continuous-manufacturing/ 2023-06-05T13:11:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cytovation-clinically-advance-cypep-1/ 2023-06-05T12:53:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pharmaessentia-pint-pharma-besremi/ 2023-06-05T10:22:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nice-bristol-myers-squibb-mavacamten/ 2023-06-05T10:08:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/evotec-open-philanthropy-henipavirus/ 2023-06-05T08:33:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/cybersecurity-in-pharma-securing-the-future/ 2023-06-05T08:11:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-nmpa-akeso-ebronucimab/ 2023-06-05T07:32:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-viral-vectors-pharmaceutical/ 2023-06-05T05:50:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-transcription-factors-for-genetically-modified-cells-pharmaceutical/ 2023-06-05T05:47:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-transcription-factors-for-aav-pharmaceutical/ 2023-06-05T05:28:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovators-immuno-oncology-t-cell-culturing-pharmaceutical/ 2024-07-31T05:54:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/meta-to-test-limiting-news-content-in-canada/ 2023-06-04T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/asco-2023-keytruda-becomes-a-new-option-in-perioperative-nsclc/ 2023-06-04T16:43:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eikon-therapeutics-106m-fund-acquisitions/ 2023-06-05T11:38:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/coherus-mark-cuban-challenge-abbvie-humira-biosimilar-yusimry/ 2023-06-11T23:38:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cms-mandates-registry-data-for-coverage-of-alzheimers-drugs/ 2023-06-02T15:59:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-touts-breast-cancer-win-with-landmark-kisqali-results/ 2023-06-02T15:56:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/revised-covid-19-vaccine-deal/ 2023-06-02T15:53:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ab-science-canadian-patent-masitinib/ 2023-06-02T13:25:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-briumvi-multiple-sclerosis/ 2023-06-02T13:19:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/anavex-life-sciences-anavex-2-73/ 2023-08-08T04:37:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lonza-acquires-synaffix-adc/ 2023-06-02T09:59:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/rentschler-biopharma-ikarovec-gene/ 2023-06-02T08:22:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-nmpa-approves-vascepa-hypertriglyceridemia/ 2023-06-02T08:39:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/uzbekistan-central-asia-fdi-star/ 2023-06-01T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-frexalimab-potential-phase-2-multiple-sclerosis-trial/ 2023-06-01T16:50:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-msd-fda-approval-prostate-cancer/ 2023-06-01T16:26:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pneumagen-raises-8-million-for-further-study-of-intranasal-antiviral/ 2023-06-01T14:17:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/index-licence-viatris-cobitolimod/ 2023-06-01T13:44:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/algernon-repirinast-patent-japan/ 2023-06-01T13:41:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/negative-fda-intercept-obeticholic-acid/ 2023-06-01T13:35:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/communications-in-life-sciences-uncovering-the-unlocked-survey-results/ 2023-06-06T08:02:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nice-pfizer-rimegepant-migraine/ 2023-06-01T10:11:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uspto-tenax-oral-levosimendan/ 2023-06-01T10:08:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/intracellular-drug-delivery-centre-rna/ 2023-06-07T10:07:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-clearance-analog-dipharmas-anda-nitisinone/ 2023-06-01T08:17:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cilnidipine-tadalafil-aisa-pharma-raynauds-disease-likelihood-of-approval/ 2024-07-05T01:50:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-3525-chia-tai-tianqing-pharmaceutical-group-cervical-cancer-likelihood-of-approval/ 2024-01-08T18:27:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexamethasone-acetate-oculis-ocular-pain-eye-pain-likelihood-of-approval/ 2025-01-19T16:51:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexamethasone-acetate-oculis-ocular-inflammation-likelihood-of-approval/ 2025-01-19T16:42:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/global-ma-activity-pharmaceutical-industry/ 2024-12-02T16:26:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/middleeastandafrica-ma-activity-pharmaceutical-industry/ 2024-12-02T16:26:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/southandcentralamerica-ma-activity-pharmaceutical-industry/ 2024-12-02T16:26:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/northamerica-privateequitydeal-activity-pharmaceutical-industry/ 2024-12-02T16:26:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/europe-ma-activity-pharmaceutical-industry/ 2024-12-02T16:26:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/asia-pacific-ma-activity-pharmaceutical-industry/ 2024-12-02T16:26:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/northamerica-ma-activity-pharmaceutical-industry/ 2024-12-02T16:26:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/europe-privateequitydeal-activity-pharmaceutical-industry/ 2024-12-02T16:26:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/asia-pacific-privateequitydeal-activity-pharmaceutical-industry/ 2024-12-02T16:27:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/india-privateequity-activity-pharmaceutical-industry/ 2024-02-16T01:51:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/china-m-a-activity-pharmaceutical-industry/ 2024-12-02T16:27:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/theus-m-a-activity-pharmaceutical-industry/ 2024-12-02T16:27:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/india-m-a-activity-pharmaceutical-industry/ 2024-12-02T16:27:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/theus-privateequity-activity-pharmaceutical-industry/ 2024-12-02T16:27:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/japan-m-a-activity-pharmaceutical-industry/ 2024-12-02T16:27:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/theuk-m-a-activity-pharmaceutical-industry/ 2024-12-02T16:27:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/fdi-landscape-algeria-2023/ 2023-05-31T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/snipr-targets-antibiotic-resistance-with-crispr-based-gene-therapy-trial/ 2023-05-31T18:21:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-proposes-new-model-for-easy-to-understand-prescription-guides/ 2023-05-31T17:58:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/anocca-raises-over-36-million-for-cancer-cell-therapy-studies/ 2023-06-07T10:07:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amylyx-regulatory-hurdle-europe-als-treatment/ 2023-05-31T17:48:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/sentiment-brexit-worsened/ 2023-05-31T13:09:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/janssen-nda-pah-combination-therapy/ 2023-05-31T12:53:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/stealth-pharmanovia-elamipretide/ 2023-05-31T12:40:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/betta-c4-therapeutics-cft8919-greater-china/ 2023-05-31T10:06:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/xtalpi-ai-drug-discovery-eli-lilly/ 2023-05-31T08:56:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-bristol-repotrectinib-nda-review/ 2023-05-31T08:08:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/university-of-sydney-ai-cancer/ 2023-05-31T08:42:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/comment/stakeholder-capitalism-requires-new-approach-to-risk/ 2023-05-30T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/early-signals-suggest-oral-serds-potential-for-more-breast-cancer-patients/ 2023-08-30T10:13:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/us-companies-2023-drug-launches-blockbuster/ 2023-06-05T07:16:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aion-labs-biomedx-launch-challenge-ai-drug-discovery/ 2023-05-31T13:53:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/catalent-fy2023-revenue-forecast/ 2024-11-22T10:58:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abiogen-acquires-effrx-to-fortify-bone-disease-portfolio/ 2023-05-30T14:12:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrivax-received-e2-5-million-government-grant-for-thermostable-vaccines/ 2023-05-30T13:55:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sk-bioscience-skycovion/ 2023-05-30T12:51:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/valneva-health-canada-chikungunya-vaccine/ 2023-05-30T12:42:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roche-canada-pcpa-vabysmo/ 2023-05-30T09:43:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sun-pharma-philogen-nidlegy/ 2023-05-30T09:54:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amplo-grant-gene-therapy-amp-201/ 2023-06-01T09:06:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/medsenic-licence-phebra-oato/ 2023-05-30T09:09:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/the-ten-largest-countries-in-the-world-and-their-investment-strengths/ 2023-05-29T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/big-data-mentions-pharmaceutical-industry/ 2024-07-18T14:39:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/filings/blockchain-mentions-pharmaceutical-industry/ 2024-04-30T02:39:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/future-of-work-mentions-pharmaceutical-industry/ 2024-07-18T14:39:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/filings/microbiome-mentions-pharmaceutical-industry/ 2024-04-30T02:39:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orphan-designated-drugs-mentions-pharmaceutical-industry/ 2024-07-18T14:39:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regenerative-medicine-mentions-pharmaceutical-industry/ 2024-07-18T14:39:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/virtual-care-mentions-pharmaceutical-industry/ 2024-07-18T14:39:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-iovance-bla-melanoma-ifileucel/ 2023-05-29T13:51:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lexicon-fda-inpefa-heart-failure/ 2023-05-29T12:38:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fivephusion-treehill-syneos-deflexifol/ 2023-05-29T09:48:25+00:00 daily 0.2